Clover Biopharmaceuticals Flips to Profit in First-Half Results

Stock News08-26 06:40

Clover Biopharmaceuticals-B (02197) reported a net profit attributable to parent shareholders of 955 million yuan for the six months ended June 30, 2026, marking a turnaround from a loss in the prior-year period.

The company recorded revenue of 179,000 yuan during the period, down 94.5% year-over-year, while other income and gains surged to 1.112 billion yuan, representing an increase of 6,200.94% compared to the same period last year. Basic earnings per share stood at 0.75 yuan.

This swing to profitability underscores the significant contribution from non-operating income streams, which more than offset the sharp decline in core revenue during the reporting period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment